Brain bleed breakthrough? new drug could stop fluid buildup without surgery

NCT ID NCT07662174

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early study tests whether a drug called sirolimus (rapamycin), given directly into the brain's fluid spaces, can prevent hydrocephalus after a severe brain hemorrhage. Hydrocephalus is a dangerous buildup of fluid that often requires a permanent surgical shunt. The trial will enroll 15 adults with bleeding from a ruptured aneurysm and will check safety, inflammation, and whether patients ultimately need a shunt.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Sirolimus (Rapamycin)
What this could lead to
If it works, this could lead to a non-surgical way to prevent hydrocephalus after brain bleeding, reducing the need for permanent shunts.
What could go wrong
This is a very early, small study with only 15 adults. The drug is delivered directly into the brain, which carries risks like infection or inflammation. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital Lunder 4 OR for adult surgeries

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.